Vision. Expertise. Success.
AbbVie Contract Manufacturing partners with companies across the globe to develop, scale and manufacture pharmaceutical products and bring them successfully to market.

Drawing on more than four decades of success as the manufacturing division of AbbVie, we have the depth of experience and the technical knowledge to navigate issues and deliver the innovative solutions customers need. We are much more than a CMO – we are your partner for success.

With foresight, scientific expertise, and passion we anticipate the technical and compliance challenges along the entire pharmaceutical development journey through to commercialization. We see the complete picture to deliver our customer's vision.

With full access to global state-of the-art facilities and world-class talent, our customers have come to depend on our service and quality to deliver real-world results.

Visit abbviecontractmfg.com for more information.

Aprecia is the biopharmaceutical leader in advanced additive manufacturing technologies. As a specialty CDMO,
we help you overcome formulation challenges. Through novel oral dosage forms, we are reimagining medicine so patients and caregivers can live their best lives.

We are Ardena, a reputable contract partner delivering drug development, manufacturing, logistics and (bio)analytical services to pharmaceutical customers globally. In parallel, we work with you to compile your regulatory dossier and to fast track your product towards compliance. Every day, we guide companies through the hurdles and challenges of drug development. Our integrated service offering helps to streamline the drug's progress to clinic and beyond. Ardena is your one source contractor for the chemical and pharmaceutical development of your valued compounds. In parallel, we provide you with full product analytical and bioanalytical support during development. Our dossier-centric approach makes a difference. We work with you to compile your regulatory dossier in parallel with drug development, saving you time, identifying hurdles and fast-tracking your product to compliance. We are experts in writing and formatting supporting CMC documentation.

Asahi Kasei is a highly diversified Japanese supplier of high-performance materials for various industries, including automotive, energy, electronics, housing and health care. In the fields of pharma- and nutraceuticals, we offer functional excipients. For many decades Asahi Kasei stands for quality, reliability and performance and is dedicated to “Creating for Tomorrow”.

Our key product is Ceolus, functional grades of microcrystalline cellulose (MCC) with outstanding compactability and flowability due to a special particle structure. This allows for avoiding typical formulation challenges like tablet mass segregation, capping, slow/fast disintegration, low tablet hardness or the changing of the API structure. Celphere, Asahi Kasei’s MCC spherical cores allow the combination of incompatible APIs in one tablet, achieve different release profiles and improve the acceptability of products. Special grades of our pregelatinized starch PC-10 can be applied for the protection of moisture sensitive APIs in the formulation.

Our functional excipients prove to be solutions to our customer’s daily challenges.

BIONANOPHARMA, part of the Insud Pharma Group, is a drug delivery company with an EU-GMP–approved facility specializing in electronebulization and electrospinning.

Our patented technology platform enables tailored drug release profiles in fiber or powder form, using room-temperature processing—ideal for thermally sensitive biologics (mAbs, ADCs, proteins, enzymes, RNA, vaccines) and complex small molecules (oligonucleotides, peptides).

Fiber formats support buccal, sublingual, transdermal, and ophthalmic patches, as well as orally dissolving films and inserts. Our powders are engineered to enhance the bioavailability of BCS Class II, III, and IV APIs, and are suitable for oral dosage forms, inhalation, nasal delivery, and long-acting injectables.

The process is fully scalable, uses commercially available pharma-grade excipients, and supports batch sizes from milligrams to tonnes—ensuring flexibility from early development to commercial production.

Cambridge Consultants (CC) is the deep tech powerhouse of the Capgemini Group. Deep tech is a mindset, a bold strategy that harnesses radical science and engineering to achieve things no-one else can. It delivers transformative business value and growth for our clients, who gain defendable commercial and operational advantage from new-to-the-world products, services and processes that they own. We overcome the ultimate business challenge: turning something that doesn’t yet exist into a reality. Our advice is built on practice, with over 750 scientists, engineers, designers and consultants working globally across more than 20,000 sq. m of state-of-the-art R&D facilities. As part of Capgemini Invent, CC is backed by 340,000+ Capgemini team members in more than 50 countries.

Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella, University Distinguished Professor at the University of Kansas’ Higuchi Biosciences Center for specific use in drug development and formulation. This unique technology has enabled several FDA-approved products, including Amgen’s Kyprolis®, Baxter International’s Nexterone®, Spectrum’s EVOMELA® and Melinta Therapeutics’ Baxdela™. There are many Captisol-enabled products currently in various stages of development.

Catalent specializes in comprehensive development, analytical and bioavailability enhancement from candidate selection to fully integrated solutions, to help get customers’ drugs to clinic faster. Using a rigorous, data-driven scientific approach, API-sparing techniques and advanced formulation technologies within a global network, Catalent helps solve complex challenges to accelerate drug development.

Corealis Pharma offers complete formulation development and clinical supply manufacture of pharmaceutical oral solid dosage forms for US, European and Canadian submissions. Each project is different and Corealis experts select the most suitable formulation and manufacturing process train for each drug substance as per its intended application. They have in-house access to well-equipped, state of the art R&D and GMP compliant operations such as API characterization, spray drying, hot melt extrusion, solid dispersion, high shear granulation, fluid-bed granulation/ drying/ coating, roller compaction, melt granulation, extrusion/spheronization, pan coating, tableting, encapsulation, packaging, patient kits preparation, warehousing, distribution and analytical services. This means that when Corealis professionals commit to a delivery date and budget, they have all the tools and resources needed to stand by their commitments and the ability to adjust quickly to any changes that may occur in the execution of a project.

Croda Pharma is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations. The company is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid delivery platforms. With a wide range of solutions for both human and animal health markets, the pharmaceutical portfolio is unsurpassed in its excellence. Croda Pharma’s products, along with its in-house formulation and regulatory expertise, allows the company to meet its customers’ most demanding formulation needs. The company is committed to enabling the next generation of drug delivery systems.

Crux was founded to address challenging technical briefs and deliver compelling solutions for the drug delivery and medical device sectors. Based in Bristol, United Kingdom, our technical team champion evidence-based problem solving, coupling world-class equipment, software and facilities with a scientific approach to maximise success. Be it discovering unmet user needs, developing novel products or deploying new technologies, our team are dedicated to solving our client’s biggest problems.

Crystal Pharmatech, Inc. is a global technology-driven CRO and CDMO with three R&D centers located in Suzhou (China), New Jersey (USA), and Toronto (Canada). We are distinguished by our comprehensive suite of services from API solid-state research, crystallization, preformulation to formulation development and GMP manufacturing. Our scientific leadership team, averaging 15 years of experience, has successfully delivered over 100 early-phase projects and commercialized 19 products for global pharmaceutical companies. With our distinctive expertise, we partner with clients to design and develop the most appropriate crystal form and formulation for further development. We have served more than 1,000 clients and assisting in the development of over 2,000 new chemical entities.
Crystal Bio, our new Business Unit, offers comprehensive biologics analytical services, including CMC-related analyses of structures, purity, degradation studies, and bioactivity correlation with MS identity.

Curia’s network of sterile drug product facilities support partners from formulation development to commercial manufacturing in various formats including vials, pre-filled syringes, and cartridges. With over 30 years of experience formulating both large and small molecules for injection, you can rely on Curia.

DelSiTech is a drug delivery and drug development company, based in Finland and is the leader in fully biodegradable, amorphous silica-based long-acting controlled release. DelSiTech's core technology, Silica Matrix, enables the delivery of virtually any API with truly controlled release over durations from a day to a year. DelSiTech Silica Matrix technology enables parenteral drug delivery through a wide variety of routes of administration, in addition to topical ocular applications of the patent protected silica composite technology. DelSiTech is currently developing controlled release products based on its Silica Matrix technology across a wide range of therapeutic areas for partners such as Bayer and the Bill & Melinda Gates Foundation

digiM is a technology leader providing CRO services in microstructure analysis and in silico modeling for the development of drug products. Combining advanced microscopic analysis with computational physics, digiM's platform provides a full spectrum understanding of drug product properties and performance. digiM works closely with developers to navigate program challenges and institutionalize knowledge libraries. In addition to services, digiM provides I2S, a cloud-based image analytics and data management platform.

EdgeOne Medical is a leading global Contract Device Development Organization, serving as the trusted testing and device development partner for more than half of the top 20 global pharmaceutical companies. As experts in compliant device development from benchtop to commercialization, we leverage our extensive industry knowledge, advanced in-house laboratory, and ISO 13485 certified Quality Management System to accelerate and derisk the development journey for our clients. EdgeOne Medical’s ability to get it “Right First Time” has made us the preferred partner for many key players in emerging pharma and big pharma. Our track record also includes supporting the combination product device development for several newly acquired emerging pharmaceutical companies representing the largest deals in the last year.

With over 30 years of expertise, Gannet BioChem is a leading specialty CDMO specializing in the development, scaling, and manufacturing of polyethylene glycol (PEG) reagents and other activated polymers—essential components in advanced biopharmaceutical and therapeutic products. Operating from a state-of-the-art 124,000 sq. ft. FDA-inspected facility in Huntsville, Alabama, Gannet BioChem delivers end-to-end GMP production, supporting clinical and commercial therapeutics. With a highly experienced team, flexible production capabilities, and a commitment to quality, Gannet BioChem provides reliable, innovative solutions to meet the evolving needs of the global biopharmaceutical industry.

excipients and cosmetic ingredients of natural origin for the health and beauty industries worldwide. Gattefossé offers to the pharmaceutical industry innovative lipid excipients for oral solubilization, bioavailability enhancement, sustained release, lubrication, and taste-masking. We provide skin penetration enhancers and emulsifiers for improved topical formulations. Every product is designed with utmost attention to safety, quality, and performance consistency. As part of Gattefossé offer, technical and regulatory support is provided by fully trained experts to accelerate customers’ drug development programs thanks to our 4 Technical Centers of Excellence in France, China, India and the United States.

Environmental and social issues have always been part of our culture. Today, Gattefossé relies on a purposeful CSR approach, Gatt’Up&Act, to build its innovation and development strategy.

Sensile Medical develops on- and off-body worn liquid drug delivery devices. Our technology offers a highly customizable, safe and cost-efficient device platform for small and large volumes. The micro-infusion pumps enable highly precise dosing at variable delivery patterns and offer various opportunities to inject a drug without the need of changing the primary packaging. Our proficiencies range from design to industrialization including manufacturing, digital health solutions. The first pump for the treatment of Parkinson`s disease was launched by EVER Pharma in 2019. Sensile Medical is a Swiss company established in 2004 and a subsidiary of Gerresheimer AG since 2018.

Glatt Pharmaceutical Services is an oral solids CDMO with an exceptional compliance history that specializes in the formulation development and process optimization of hard to craft formulations and challenging modified release profiles. Glatt’s core technologies include solubility enhancement via production of ASDs using fluid bed technology, taste masking, and complex multi-particulate dosage forms - all developed with robust, stable, scalable pharmaceutical processes. Glatt offers large scale solvent processing and handles DEA substances schedule l through V. Glatt has you covered from small scale development through seamless scale up to large scale commercial manufacturing.

Grand River Aseptic Manufacturing (GRAM) is a leading contract development and manufacturing organization (CDMO) specializing in sterile injectable fill-and-finish services for liquid and lyophilized vials, syringes, and cartridges. We are committed to advancing patient care by providing our clients with the experience, technology, and quality record necessary for effective clinical trials and successful commercialization.

GRAM adds value for our clients through strategic partnerships with innovators in drug delivery devices, offering tailored solutions designed for autoinjectors and on-body delivery systems. Our emphasis on collaboration allows us to speed up the delivery of innovative therapies, ensuring that our clients' products reach the market and benefit patients into the future.

Hovione offers customized services and innovative solutions from drug substance to drug product, with all activities performed at the same site. Hovione provides a fully integrated service for clinical and small commercial scale complex drug product development and manufacturing as well as formulation development for highly sophisticated inhalation and other formulations both for small molecules and biologics. As the Leader in Commercial Spray Drying, Hovione can handle projects from early-phase development to commercial and accelerates your time to market. Our particle engineering technologies can address challenges in solubility enhancement, lung delivery, modified release and taste-masking applications and can handle highly potent compounds. For biopharmaceuticals Hovione is investing by partnering in specialized particle engineering technologies, namely spray drying, aseptic spray freeze drying, nanoparticles and microemulsions. We do well what is difficult, to give our customers what they cannot find elsewhere.

InnoCore Pharmaceuticals is a biopharmaceutical drug delivery company specialized in the development of long-acting injectables (LAI) for the treatment of several (chronic) diseases e.g. oncology, pain, atherosclerosis, macular degeneration, CV, osteoarthritis. Using biodegradable polymers for microspheres, gels and implants (including ISFI) we have a unique platform to control sustained drug delivery of small molecules, peptides and proteins (including mAbs) from days, weeks to months (6).

At InnoGI Technologies, we lead the way in sustainable oral drug and nutritional research by advancing gastrointestinal (GI) modeling. We provide innovative services to the pharmaceutical and food industries, specializing in GI modeling through our advanced TIM (The Intestinal Models) models. These dynamic in vitro models mimic the entire GI tract, delivering deep, data-driven insights into digestion, absorption, and microbiome interaction

By delivering predictive, physiologically relevant results, we help our clients and partners better understand how their products behave during digestion—reducing development risks, accelerating time to market, and supporting a future with less reliance on animal testing.

With over 30 years of experience in GI modeling and a track record of 260+ scientific publications InnoGI is your reliable partner for confident decision making!

KBI Biopharma is a global CDMO providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. With each of its 500+ customer partners, KBI works closely to personalize and rapidly accelerate drug development programs.

Global partners are utilizing KBI’s technologies to advance more than 170 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. With world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. KBI helps partners advance drug candidates to the market. KBI serves its global customers with six locations in Europe and the USA. www.kbibiopharma.com.

KERN LIEBERS, a medium-sized family company based in southwest Germany, is a global technology leader for the engineering and production of highly complex components and hybrid assemblies at over 40 locations around the world. With many years of experience in the watch industry since 1888, KERN LIEBERS has also been successful in the manufacture of medical components and products for more than 30 years. Thanks to our wide range of in-house technologies, we develop solutions for specific products, cleanliness and compatibility.

Specialized in SMART SPRINGS and SMART PARTS for specific drug delivery systems by using customized design elements for trigger mechanisms and high security parts.

ONE KERN LIEBERS. WE LIVE TECHNOLOGY. WE LIVE VALUE. WE ARE A GLOBAL FAMILIY. WE ARE SHAPING THE FUTURE.

Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of approximately 18,500 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. We support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.

In Advanced Synthesis, we apply more than 125 years’ expertise in classic and complex chemistry to the manufacturing of small molecules, highly potent APIs, antibody-drug conjugates and bioconjugates.

Find out more at www.lonza.com
Follow @Lonza on LinkedIn

Lubrizol provides excipients that enhance the solubility and bioavailability of active ingredients. Apinovex™ Polymers are used for amorphous solid dispersions, improving the solubility of poorly soluble drugs. Apisolex™ Polymers enhance solubility in injectable formulations, offering high drug loading and stability. Carbopol® Polymers are high molecular weight polyacrylic acid polymers used in various formulations for their thickening and stabilizing properties. We also supply a range of other ingredients listed on the FDA’s Inactive Ingredient Database (IID) that can help improve the feel and performance of topical pharmaceutical formulations.

Nanoform is an innovative nanoparticle medicine-enabling company that works together with global Pharma and biotech partners to devise solutions to complex formulation challenges. Nanoform’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) process can produce uniform nanoparticles as small as 10nm, facilitating transport even across biological barriers. As particles smaller than 100nm have significantly enhanced surface areas, this can increase drug dissolution rates and improve bioavailability, allowing drugs of poor solubility in the pharmaceutical pipeline to progress to clinical development. CESS® enables lower dosage and safer products to be developed with reduced side-effects and permits combination therapies, which would otherwise be prohibited by the large dosages of either drug. The award-winning technology is also ushering in a new era of ocular, pulmonary and transdermal drug delivery applications, along with enhanced delivery of drug particles across the blood-brain barrier.

NISSO HPC (Hydroxypropyl Cellulose) was first sold in Japan in 1969 and is globally approved for use as a pharmaceutical and nutraceutical excipient and as a binder for granulation, direct compression, and as a solubility enhancement matrix. NISSO HPC has been fully IPEC GMP compliant since 2010.

NISSO SSF (Sodium Stearyl Fumarate) is a lubricant (pharmaceutical additive) in the production of tablets. It is primarily used in tableting and dry granulation as a means of preventing tablet failure. The presence of hydrophilic groups in the molecule improves the disintegration time of the tablets, making it suitable for use in orally disintegrating (OD) tablets. Using NISSO SSF as a lubricant can suppress the effects of over-mixing tableting powders and improving the tablets physical properties, making it suitable for the continuous pharmaceutical manufacturing that has been gaining attention in recent years.

Nippon Soda/NISSO provides Japanese high-quality and highly functional excipients.

Onyx Scientific, the CDMO division of Ipca Laboratories, has specialized in small molecule drug substance development and manufacturing for 25 years. From our MHRA-licensed facilities in the UK, we provide seamless support for early development for candidate APIs, clinical phase production, and commercial supply. Our dedicated solid-state and analytical chemistry teams accelerate development timelines, offering both integrated services and full-service outsourced solutions to complement your in-house efforts.
With extensive expertise in early-stage development, we adopt a pragmatic, fit-for-purpose approach that prioritizes rapid process development while paving the way for future GMP campaigns. For projects requiring scale-up beyond Phase II, we ensure continuity through seamless transitions within our global network, leveraging sister sites and expert teams in the USA and India to meet your long-term manufacturing needs.

Pace® Life Sciences provides a full suite of contract CMC development, clinical trials materials manufacturing, regulatory compliance, consulting, and facility support services to the pharmaceutical, biopharmaceutical, and gene therapy industries. Our network of CDMO sites consists of GMP analytical testing laboratories and manufacturing support service centers. Our experienced, highly trained industry experts and our investment in state-of-the-art development and manufacturing facilities emphasize our commitment to efficiently advancing client programs through the clinic to commercialization. We are dedicated to delivering the best and most reliable services with positive customer experiences across all channels of our business.

Pfanstiehl Inc. is a cGMP Manufacturer of High Purity Low Endotoxin components such as Trehalose, Sucrose, Mannitol, Maltose, Galactose (non-animal), Mannose and Amino Acids such as L-Arginine, Histidine, Glutamine and Methionine for Biologics, Biosimilars, Vaccines, Cell Culture Media and Injectables (liquid & lyo) located in Waukegan Illinois USA. Pfanstiehl has been in operation since 1919, focusing on both Biopharmaceutical excipients / critical components & Pharmaceutical HPAPIs / APIs (generic and on contract manufacturing base). Pfanstiehl specializes in isolation, purification, custom synthesis and scale-up development of regulated, high purity and low endotoxin Injectable Formulation Ingredients, Pharmaceutical Intermediates and Active Pharmaceutical Ingredients, in gram to multi-ton commercial quantities.

Quotient Sciences is a drug development services organization, dedicated to accelerating the development of new drugs for patients around the world. We provide formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform, which is proven to shorten development timelines and reduce associated costs.

At SCHERDEL Medtec, we don’t just provide solutions, we provide care. Making components for the medical industry offers the unique privilege to our employees and the community. We’re proud to provide crucial, essential medical components to the people who need them. Scherdel employees understand that we manufacture more than just springs, we manufacture pieces of hope and health to individuals in need. At SCHERDEL Medtec, we believe that healthcare consists of two equal parts, health and care.

SCHERDEL Medtec, is part of the SCHERDEL Group. With about with over 6,000 employees at 32 locations worldwide, the SCHERDEL Group is a family-owned, leading company in the field of metal-forming with core competence in the production of engineering springs, stamping parts and assemblies for the pharmaceutical market as well as of vehicle components.

Why should you choose Scherdel Medtec:
• Global footprint with production plants in EU, North America and China
• Customized engineering solutions
• Numerical simulation of application performance
• Customized cleaning and packaging (including ISO 7 conditions)
• Patented and customizable detangling solutions
• Spring solutions for high- and low viscosity Drug Delivery Devices
• ISO 13485 certified quality management system

We represent a global group of satellite locations with state of the art solutions for Industry, mobility and medical applications. Our development team becomes involved in product design right from the start following through into serial production. Forming optimized processes and using intelligent logistics turning innovative ideas into moving solutions. 12 countries, 32 locations, 42 plants, 6,000 employees worldwide

Serán BioScience, LLC is a leading sci¬ence-based CDMO that specializes in a variety of drug delivery and formu¬lation approaches suited to optimizing bioavailability. Serán’s experienced formulation team will work with you to identify an appropriate technology and formulation strategy to meet your program’s unique needs. Our comprehensive approach to formulation design considers the physiochemical properties of the API, the target product profile, and your program’s objectives and constraints to develop scalable formulations using efficient and material-sparing approaches.

Whether considering enabling technologies (amorphous solid dispersions, lipid formulations, particle size reduction techniques) or conventional approaches, we comprehensively assess technology options to consider bio-performance, stability, manufacturability, and drug product design – aiming to deliver you the simplest approach that meets your program’s needs.

Serán provides capsules (enteric or IR), tablets (from minitablets to large format caplets), multi-particulates (coated beads), and powder-in-bottle formulations. Our solid dosage forms are engineered for a wide range of formulation approaches such as overcoming solubility challenges and to enable extended-release. We complement industry-best production practices with the finest manufacturing equipment available to produce dosage forms that perform predictably and reliably.

QPharma, Foster Delivery Science and Disphar International are now Sever Pharma Solutions. Together we have formed a new CDMO, a company that can provide our customers with unique capabilities and expertise. Sever Pharma Solutions brings your pharmaceutical ideas to life by offering expertise in high potent drug development, a drive to enhance performance, a passion for perfection, and a commitment to be your partner through the whole journey. We can enhance your reach by ensuring that your products can benefit patients all over the world. We can enhance your efficiency by providing you with a complete value chain to offer you an optimized end-to-end solution. We can enhance your product by adding value through all development and manufacturing processes. We can enhance your outcome by adding value through all development and manufacturing processes. We are Extrusion. We are Polymer Based Dosage Forms. We are Formulation of Highly Active dosage forms. We are Long Acting Implants. We are Solid Dosage Forms. We are Injection Molding. We are Aseptic Fill and Finish. We are Sever Pharma Solutions.

Singota Solutions is a woman-owned CDMO with a superior record of quality performance. We focus on helping clients overcome obstacles in any phase of the injectable drug development pipeline. Singota specializes in collaborating with early-stage companies, partnering with you to de-risk and expedite the progression of your promising injectable medicine through the development journey faster. Hundreds of companies trust us to get it right the first time. Get to know us and learn how we can accelerate your injectable drug’s path to market.

Singota’s 20 years of success means we have the expertise to deliver just what you need in drug development and small batch aseptic manufacturing services, when you need it. In 8 years of GMP batch manufacturing, we have had zero sterility failures.

As a “one stop shop” for early-stage BioPharma, Singota offers:
• cGxP-controlled laboratory & formulation development services
• Precision temperature-controlled storage in the US, Switzerland, and Italy including -80°C, -40°C, -20°C, 2-8°C, and 15-25°C
• Dispensing & sampling in Grade C suites
• Transportation simulation solutions & testing
• Labelling & kitting services
• Robotic, aseptic manufacturing for injectable medicines

A 100+ employee company based in Bloomington, Indiana, Singota stands ready to help you successfully formulate and develop your injectable pharmaceutical product. Our robust formulation development and analytical, process, and method development services mean we get your innovative injectable medicine to the clinic, and to patients, faster.

https://www.linkedin.com/company/singota-solutions

SPERA PHARMA is responsible for the entire CMC process, from R&D through application; it provides services that meet the needs of customers.

Founded in 1949, Stevanato Group is a leading global provider ofdrug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. TheGroup delivers an integrated, end-to-end portfolio of products,processes and services that address customer needs across the entire drug lifecycle at each of the development, clinical andcommercial stages. Stevanato Group’s core capabilities in scientificresearch and development, its commitment to technical innovationand its engineering excellence are central to its ability to offer value-added solutions to clients.

Syngene International Limited is a leading Contract Research & Development/Manufacturing Organization (CRO/CDMO) with 450+ active clients and 400+ patent credits. We have 30+ years of rich experience working with global clients across the Drug Discovery and Development continuum.

What sets us apart, is our full-service, integrated capabilities all under one roof that lower the cost of innovation and enable faster approval and commercialization of your drug development product.

Processing and packaging for a better life – this is what 5,800 Syntegon employees work for every day. Be it with individual machines, systems, or services, we help you – our customers in the global pharmaceutical and food industries – to improve people's lives. For that we look back on more than 160 years of experience. In the pharma sector, our intelligent solutions enable the safe and high-quality production, processing, filling, inspection, and packaging of your liquid and solid pharmaceuticals. In the food industry, our flexible and reliable technologies produce and package confectionery, dry food, frozen food, and dairy products. With 1,100 service experts and a comprehensive service portfolio throughout the entire machine lifecycle from spare parts management to digital line optimization, Syntegon lays the foundation for your smooth production processes. In everything we do, our more than 30 sites in almost 20 countries keep a firm eye on our impact on the environment and society. Syntegon is a leader in the development of sustainable packaging solutions, reduces the energy consumption of its machines and pursues ambitious goals to lower its emissions.

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner, and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Patheon, under which we provide industry-leading pharma services for drug development, clinical trial logistics, and commercial manufacturing. We partner with customers in the pharmaceutical, biotech, and life sciences industries as their trusted CDMO to deliver medicine to patients faster. We believe that doing this successfully not only requires science, technology, and world-class expertise, but also requires a strategic partnership—bonded by key elements such as trust, communication, and collaboration.

Triclinic Labs is a premier contract research organization focused on solid-state chemical development and comprehensive materials analysis for pharmaceutical, medical device, and fine-chemical clients. Leveraging decades of experience, the company excels in polymorph and salt, form screening and selection, cocrystal screening and formulation, and amorphous material development, as well as crystallization method optimization and particle/habit engineering.
Their state-of-the-art analytical chemistry services encompass X-ray powder diffraction (XRPD), Electron and single crystal diffraction, thermal analysis (TGA/DSC), spectroscopy (Raman, FT-IR, solid-state NMR), chromatography (LC/GC), microscopy (optical, electron, high-speed), Coupled techniques (Mass spectrometry with LC and GC), elemental analysis (EDX, ICP-MS), water content determination (KF, DVS), and particle-size characterization. Advanced offerings include predictive materials modeling, peptide characterization, and specialty inorganic, petrochemical, and contaminant identification analyses.
As a cGMP-compliant, DEA Schedule I–V registered and FDA-inspected laboratory, Triclinic Labs provides method development, validation, and release testing, robust intellectual property support, and regulatory guidance to accelerate timelines and mitigate development risks. Their integrated approach ensures clients achieve reproducible, scalable solutions with maximum efficiency and confidence.

Uncountable provides a Unified R&D Laboratory Informatics Platform that revolutionizes how R&D teams explore, analyze, and share scientific data, helping accelerate the pace of innovation. Founded in 2016, Uncountable's all-in-one AI-powered solution helps enterprise R&D organizations modernize and streamline data management and analysis – providing scientists with a single and easily accessible web-based platform that comes fully integrated with all the critical data systems and tools used in the laboratory, including electronic lab notebooks (ELNs), laboratory information management systems (LIMS), product lifecycle management (PLM), quality management systems (QMS), advanced visualization and reporting tools, and more.

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.

Headquartered in Exton, Pennsylvania, West in its fiscal year 2024 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.

WuXi STA, an integrated part of WuXi AppTec, is an industry-leading pharmaceutical development and manufacturing capability and technology platform serving the life sciences industry with operations across North America, Europe and Asia. As an innovative Contract Development, and Manufacturing Organization (CDMO) for small molecule new drug development, WuXi STA offers our worldwide partners efficient, flexible, and high-quality solutions from preclinical to commercial uses.

Zerion Pharma A/S is a pharmaceutical company aspiring to transform the pharmaceutical landscape for the formulation of poorly soluble drugs that are currently not reaching their therapeutic potential.

The company was established in 2019 as a spinout from the University of Copenhagen based on a decade of research. Zerion Pharma has pioneered the Dispersome® technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and therapeutic options for patients.

The Dispersome® technology is based around a class of novel excipient, namely beta-lactoglobulin (BLG), to formulate poorly soluble small molecule drugs into stable amorphous drug delivery systems with a high drug load. By increasing solubility and dissolution rate, the Dispersome® platform aims at improving bioavailability and therapeutic outcomes and reducing adverse effects in patients. The Dispersome® technology is well accepted with no safety risks and is compatible with standard solid oral dosage form manufacturing.